| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Operating activities | ||||||
Net loss | ||||||
-290,170 | -80,546 | -47,671 | -6,227 | -1,450 | 689 | |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation | ||||||
932 | 431 | 437 | 682 | 1,819 | 2,512 | |
Amortization of debt issuance costs and implied interest | ||||||
1,374 | 888 | 138 | - | - | - | |
Stock-based compensation expense | ||||||
26,381 | 10,550 | 6,530 | 2,367 | 2,075 | 1,523 | |
Loss on extinguishment of debt | ||||||
- | -1,007 | - | - | - | - | |
Provision for deferred taxes on income | ||||||
- | - | - | - | 17,802 | 18,316 | |
Loss on disposal of property and equipment | ||||||
- | - | - | - | -2 | -203 | |
Changes in operating assets and liabilities: | ||||||
Prepaid expenses and other current assets | ||||||
469 | 1,154 | 778 | 1,218 | -81 | 791 | |
Other assets | ||||||
-410 | -20 | 519 | 438 | -281 | 532 | |
Accounts payable | ||||||
-2,114 | 1,955 | -1,763 | 299 | 2,754 | -1,656 | |
Accrued direct research, other current, and long-term liabilities | ||||||
11,975 | 4,417 | 6,973 | 3,080 | -486 | 2,925 | |
Payable to collaborators | ||||||
216,862 | - | - | - | - | - | |
Federal income tax receivable/payable | ||||||
- | - | - | 31,926 | -17,903 | -61,127 | |
Deferred revenue | ||||||
-216,332 | -21,351 | -46,603 | -49,730 | -49,595 | -50,692 | |
Net cash used in operating activities | ||||||
-251,151 | -83,783 | -83,256 | -19,259 | -44,620 | -88,630 | |
Investing activities | ||||||
Sales/disposals of fixed assets | ||||||
- | - | 1 | - | - | - | |
Sales/disposals of fixed assets | ||||||
- | - | - | -1 | -12 | -43 | |
Purchases of property and equipment | ||||||
2,673 | 679 | 344 | 340 | 272 | 183 | |
Net cash used in investing activities | ||||||
-2,673 | -679 | -343 | -339 | -260 | -140 | |
Proceeds from issuance of common stock | ||||||
492,453 | 233,496 | 108,910 | 64,705 | - | - | |
Payments on deferred offering costs | ||||||
71 | 627 | 404 | 2,607 | 864 | - | |
Proceeds from long-term debt | ||||||
75,000 | 60,000 | 20,000 | - | - | - | |
Payments on deferred issuance costs | ||||||
576 | 2,290 | 524 | - | - | - | |
Exercise of options | ||||||
13,400 | 1,885 | 660 | 4 | 39 | 1 | |
Other shareholder transactions | ||||||
107 | 8 | 5 | - | - | - | |
Proceeds from payments of shareholder promissory notes | ||||||
- | - | - | 265 | - | - | |
Payment of capital lease obligation | ||||||
- | - | - | 45 | 45 | - | |
Net cash provided by financing activities | ||||||
580,358 | 292,472 | 128,647 | 62,322 | -870 | 1 | |
Net decrease in cash and cash equivalents | ||||||
326,534 | 208,010 | 45,048 | 42,724 | -45,750 | -88,769 | |
Supplemental disclosures | ||||||
Cash paid for interest | ||||||
8,207 | 4,741 | 1,164 | - | - | - | |
Accrued deferred offering cost | ||||||
447 | - | - | - | 1,129 | - | |
Non-cash activity: | ||||||
Right-of-use assets obtained in exchange for lease obligations | ||||||
9,068 | - | - | - | - | - | |
Income taxes paid | ||||||
- | - | - | - | 1,249 | 59,500 | |
Purchases of equipment in accounts payable, accrued direct research, other current, and long-term liabilities | ||||||
302 | 492 | 13 | 20 | 187 | - | |
Equipment acquired under capital lease | ||||||
- | - | - | - | - | 135 | |